Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients.

Tani T, Naoki K, Yasuda H, Arai D, Ishioka K, Ohgino K, Yoda S, Nakayama S, Satomi R, Terai H, Ikemura S, Sato T, Soejima K.

Cancer Chemother Pharmacol. 2019 Nov;84(5):1065-1071. doi: 10.1007/s00280-019-03934-y. Epub 2019 Sep 6.

PMID:
31493177
2.

Drug-induced pneumonitis following the administration of laninamivir octanoate: The first two reported cases.

Ogawa T, Tanaka K, Ohgino K, Omori N, Betsuyaku T, Sayama K.

J Infect Chemother. 2019 Dec;25(12):1043-1046. doi: 10.1016/j.jiac.2019.05.008. Epub 2019 Jun 6.

PMID:
31178281
3.

Detection of EGFR T790M in a Large Amount of Malignant Ascites Cellblock.

Ishioka K, Sasada S, Ohgino K, Sakai T, Takahashi S, Xu C, Sugihara K, Nakamura M.

Gan To Kagaku Ryoho. 2018 Aug;45(8):1185-1187.

PMID:
30158416
4.

Prognostic Understanding at Diagnosis and Associated Factors in Patients with Advanced Lung Cancer and Their Caregivers.

Sato T, Soejima K, Fujisawa D, Takeuchi M, Arai D, Nakachi I, Naoki K, Kawada I, Yasuda H, Ishioka K, Nukaga S, Kobayashi K, Masaki K, Inoue T, Hikima K, Nakamura M, Ohgino K, Oyamada Y, Funatsu Y, Terashima T, Miyao N, Sayama K, Saito F, Sakamaki F, Betsuyaku T.

Oncologist. 2018 Oct;23(10):1218-1229. doi: 10.1634/theoncologist.2017-0329. Epub 2018 Aug 17.

5.

Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001).

Miyawaki M, Naoki K, Yoda S, Nakayama S, Satomi R, Sato T, Ikemura S, Ohgino K, Ishioka K, Arai D, Namkoong H, Otsuka K, Miyazaki M, Tani T, Kuroda A, Nishino M, Yasuda H, Kawada I, Koh H, Nakamura M, Terashima T, Sakamaki F, Sayama K, Betsuyaku T, Soejima K.

Mol Clin Oncol. 2017 Mar;6(3):409-414. doi: 10.3892/mco.2017.1154. Epub 2017 Feb 6.

6.

Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer.

Miyawaki M, Yasuda H, Tani T, Hamamoto J, Arai D, Ishioka K, Ohgino K, Nukaga S, Hirano T, Kawada I, Naoki K, Hayashi Y, Betsuyaku T, Soejima K.

Mol Cancer Res. 2017 Jan;15(1):106-114. doi: 10.1158/1541-7786.MCR-16-0211. Epub 2016 Oct 5.

7.

Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells.

Tani T, Yasuda H, Hamamoto J, Kuroda A, Arai D, Ishioka K, Ohgino K, Miyawaki M, Kawada I, Naoki K, Hayashi Y, Betsuyaku T, Soejima K.

Mol Cancer Ther. 2016 Jan;15(1):162-71. doi: 10.1158/1535-7163.MCT-15-0084. Epub 2015 Dec 18.

8.

Prognostic implication of PTPRH hypomethylation in non-small cell lung cancer.

Sato T, Soejima K, Arai E, Hamamoto J, Yasuda H, Arai D, Ishioka K, Ohgino K, Naoki K, Kohno T, Tsuta K, Watanabe S, Kanai Y, Betsuyaku T.

Oncol Rep. 2015 Sep;34(3):1137-45. doi: 10.3892/or.2015.4082. Epub 2015 Jun 25.

9.

A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer.

Ikemura S, Naoki K, Yasuda H, Kawada I, Yoda S, Terai H, Sato T, Ishioka K, Arai D, Ohgino K, Kamata H, Miyata J, Kabata H, Betsuyaku T, Soejima K.

Jpn J Clin Oncol. 2015 Apr;45(4):356-61. doi: 10.1093/jjco/hyu226. Epub 2015 Jan 22.

PMID:
25612761
10.

A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer.

Soejima K, Naoki K, Ishioka K, Nakamura M, Nakatani M, Kawada I, Watanabe H, Nakachi I, Yasuda H, Satomi R, Nakayama S, Yoda S, Ikemura S, Terai H, Sato T, Ohgino K, Arai D, Tani T, Kuroda A, Nishino M, Betsuyaku T.

Cancer Chemother Pharmacol. 2015 Mar;75(3):513-9. doi: 10.1007/s00280-014-2673-8. Epub 2015 Jan 7.

PMID:
25563719
11.

FOXD1 expression is associated with poor prognosis in non-small cell lung cancer.

Nakayama S, Soejima K, Yasuda H, Yoda S, Satomi R, Ikemura S, Terai H, Sato T, Yamaguchi N, Hamamoto J, Arai D, Ishioka K, Ohgino K, Naoki K, Betsuyaku T.

Anticancer Res. 2015 Jan;35(1):261-8.

PMID:
25550559
12.

Methylation-induced downregulation of TFPI-2 causes TMPRSS4 overexpression and contributes to oncogenesis in a subset of non-small-cell lung carcinoma.

Hamamoto J, Soejima K, Naoki K, Yasuda H, Hayashi Y, Yoda S, Nakayama S, Satomi R, Terai H, Ikemura S, Sato T, Arai D, Ishioka K, Ohgino K, Betsuyaku T.

Cancer Sci. 2015 Jan;106(1):34-42. doi: 10.1111/cas.12569. Epub 2014 Dec 8.

13.

Long‑term exposure to gefitinib induces acquired resistance through DNA methylation changes in the EGFR‑mutant PC9 lung cancer cell line.

Terai H, Soejima K, Yasuda H, Sato T, Naoki K, Ikemura S, Arai D, Ohgino K, Ishioka K, Hamamoto J, Kanai Y, Betsuyaku T.

Int J Oncol. 2015 Jan;46(1):430-6. doi: 10.3892/ijo.2014.2733. Epub 2014 Oct 29.

PMID:
25353970
14.

Multiple roles of extracellular fibroblast growth factors in lung cancer cells.

Suzuki T, Yasuda H, Funaishi K, Arai D, Ishioka K, Ohgino K, Tani T, Hamamoto J, Ohashi A, Naoki K, Betsuyaku T, Soejima K.

Int J Oncol. 2015 Jan;46(1):423-9. doi: 10.3892/ijo.2014.2718. Epub 2014 Oct 21.

PMID:
25353145
15.

Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancer.

Ohgino K, Soejima K, Yasuda H, Hayashi Y, Hamamoto J, Naoki K, Arai D, Ishioka K, Sato T, Terai H, Ikemura S, Yoda S, Tani T, Kuroda A, Betsuyaku T.

Lung Cancer. 2014 Jan;83(1):90-6. doi: 10.1016/j.lungcan.2013.10.016. Epub 2013 Oct 30.

PMID:
24239165
16.

Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC.

Terai H, Soejima K, Yasuda H, Nakayama S, Hamamoto J, Arai D, Ishioka K, Ohgino K, Ikemura S, Sato T, Yoda S, Satomi R, Naoki K, Betsuyaku T.

Mol Cancer Res. 2013 Jul;11(7):759-67. doi: 10.1158/1541-7786.MCR-12-0652. Epub 2013 Mar 27.

Supplemental Content

Loading ...
Support Center